
94th EAS Congress 2026
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 94th EAS Congress 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
EAS Congress 2026
Event type: Medical congress, cardiovascular research, lipidology, atherosclerosis, clinical science, biotech, pharmaceuticals, diagnostics, medical education
Estimated attendance: Likely in the range of several thousand attendees, with a mix of physicians, researchers, academics, clinical specialists, industry partners, exhibitors, and scientific delegates. Final footfall depends on the host city, program size, and satellite symposia.
1) Who attends: Buyers / attendees
EAS Congress 2026 is a highly specialized scientific and medical congress, so the audience is not broad consumer traffic. It is a strong high-value B2B and B2B2C healthcare audience where the most relevant “buyers” are the professionals, institutions, and companies involved in cardiovascular care, lipid management, diagnostics, research, and treatment innovation.
The attendee base typically includes:
- Cardiologists and preventive cardiology specialists
- Lipidologists, endocrinologists, internists, and vascular medicine experts
- Clinical researchers working in atherosclerosis, dyslipidemia, and metabolic disease
- Hospital decision-makers and academic medical center faculty
- Pharma teams from medical affairs, clinical development, market access, and brand teams
- Biotech and diagnostics companies focused on cardiovascular and metabolic disease
- Medical device and lab technology companies with relevant product lines
- Association leaders, KOLs, guideline experts, and educators
- Scientific publishers, research organizations, CROs, and trial networks
From a buyer-list perspective, the most valuable contacts are not just “attendees” in the broad sense, but those who influence treatment pathways, purchasing decisions, clinical adoption, research partnerships, education programs, and scientific collaborations.
2) Where the show is happening + attendee geographic origin
The exact city and venue should be confirmed from the official congress page for EAS Congress 2026, because conference locations can change from year to year. Once the venue is finalized, the geographic origin of attendees usually follows a very clear pattern for a European medical congress:
- Primary base: Europe, with strong representation from the host country and neighboring countries
- Secondary base: UK, Middle East, North America, Asia-Pacific, and selected global research hubs
- International attendance: Usually strong, because the subject matter is globally relevant to cardiology, lipid science, and chronic disease management
For outreach and buyer segmentation, this means the attendee base is usually:
- Local/regional around the host city and country for onsite hospital, academic, and vendor participation
- National through professional medical societies, university hospitals, and domestic pharma teams
- Global in scientific relevance, especially for multinational pharma, biotech, diagnostics, and research organizations
3) Audience reach: Local / National / Global
EAS Congress 2026 should be considered a global scientific event with a strong European core. The congress is not limited to one country’s market because atherosclerosis, lipid disorders, and cardiovascular disease are universal clinical priorities.
Reach classification: Global, with regional European concentration
Why this matters for list building:
- It attracts international experts who often influence guidelines and treatment protocols
- It is relevant for multinational commercial teams in pharma and diagnostics
- It can produce high-quality leads across medical affairs, R&D, market access, and education
4) Sample buyer company names + websites
Below is a sample buyer table with organizations that are generally strong fits for this type of congress. These are not random names; they are the kind of companies that are likely to sponsor, exhibit, send delegates, monitor scientific trends, recruit expert advisors, or engage in disease-area marketing and evidence-generation.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Amgen | amgen.com | Medical Science Liaison, Cardiovascular / Director, Medical Affairs | Strong cardiovascular and lipidology interest; highly relevant for scientific exchange and disease-area education. |
| 2 | Novartis | novartis.com | Global Brand Director, Cardiovascular / Medical Affairs Manager | Major player in cardiovascular therapies and evidence-driven congress engagement. |
| 3 | Sanofi | sanofi.com | Medical Affairs Lead, Cardiometabolic / Market Access Manager | Relevant for cardiometabolic disease, patient pathways, and therapy adoption. |
| 4 | Regeneron | regeneron.com | Medical Director, Cardiology / Clinical Development Lead | Strong fit for innovative biologics and scientific engagement in lipid-related disease. |
| 5 | Pfizer | pfizer.com | Director, Medical Affairs / Scientific Communications Manager | Large-scale medical congress participation and broad cardiovascular interest. |
| 6 | Bristol Myers Squibb | bms.com | Scientific Director, Cardiovascular / Medical Strategy Lead | Useful for engaging experts in cardiovascular outcomes and evidence generation. |
| 7 | AstraZeneca | astrazeneca.com | Director, Cardiovascular Medical Affairs / Regional Medical Lead | Very strong fit for cardiometabolic disease, scientific congress activity, and clinical education. |
| 8 | Merck | merck.com | Brand Manager, Cardiovascular / Clinical Research Manager | Relevant for chronic disease, clinical research, and specialist engagement. |
| 9 | Abbott | abbott.com | Marketing Director, Diagnostics / Product Manager, Cardiology | Fits diagnostic testing, lab science, and clinical cardiovascular screening solutions. |
| 10 | Roche | roche.com | Medical Affairs Leader / Diagnostics Business Manager | Excellent fit for diagnostics, biomarker science, and precision medicine conversations. |
| 11 | Siemens Healthineers | siemens-healthineers.com | Business Development Manager, Diagnostics / Clinical Marketing Manager | Strong diagnostics angle where cardiovascular and metabolic testing matter. |
| 12 | Bayer | bayer.com | Medical Affairs Manager, Cardiology / Scientific Advisor | Relevant for cardiology-focused scientific promotion and clinician education. |
| 13 | Eli Lilly and Company | lilly.com | Medical Director, Cardiometabolic / HEOR Manager | Highly relevant where cardiometabolic disease intersects with metabolic care and outcomes research. |
| 14 | GSK | gsk.com | Medical Strategy Lead / External Affairs Manager | Good fit for scientific engagement, evidence generation, and professional networking. |
| 15 | Thermo Fisher Scientific | thermofisher.com | Product Manager, Life Sciences / Business Development Director | Strong for lab tools, biomarker research, translational science, and clinical research support. |
| 16 | F. Hoffmann-La Roche | roche.com | Global Medical Lead / Scientific Engagement Manager | Deep fit for precision diagnostics and cardiovascular research partnerships. |
| 17 | Medtronic | medtronic.com | Director, Clinical Affairs / Cardiac Portfolio Manager | Useful if the congress includes procedural, device, or risk-management conversations. |
| 18 | Bio-Rad Laboratories | bio-rad.com | Regional Sales Manager / Clinical Diagnostics Marketing Manager | Strong diagnostics and research audience fit. |
| 19 | Sysmex | sysmex.com | Marketing Manager, Clinical Diagnostics / Sales Director | Relevant for lab medicine and testing workflows tied to cardiovascular care. |
| 20 | IQVIA | iqvia.com | Director, Real World Evidence / Healthcare Research Lead | Excellent fit for analytics, trial support, patient data, and commercial intelligence. |
Top 5 best sample buyers to send first: Amgen, Novartis, Sanofi, AstraZeneca, and Abbott. These are especially strong because they combine scientific depth, commercial budgets, and a real need to engage with cardiometabolic experts.
5) Job profiles, industries & event type
For buyer-list building, the most useful contacts are those who shape medical strategy, evidence, treatment awareness, product adoption, and research partnerships. Depending on your client’s product, the target titles can be adjusted to scientific, commercial, or operational profiles.
Best job profiles to target:
- Medical Director
- Director of Medical Affairs
- Medical Science Liaison
- Scientific Advisor
- Clinical Development Lead
- Brand Director, Cardiovascular
- Global Product Manager
- Market Access Manager
- Health Economics & Outcomes Research Manager
- Clinical Research Manager
- R&D Director
- Lab Solutions Manager
- Diagnostics Marketing Manager
- Key Opinion Leader / Professor / Consultant
- Program Director, Cardiometabolic Care
Best industry filters to use:
- Pharmaceuticals
- Biotechnology
- Hospital & Health Care
- Medical Devices
- Research
- Information Services
- Market Research
- Health, Wellness & Fitness
- Higher Education
- Professional Training & Coaching
- Medical Practice
- Philanthropy
- Diagnostics-related companies through keyword targeting
Event type fit: This is ideal for targeting scientific, clinical, and commercial healthcare stakeholders rather than general business buyers. If your client sells solutions into healthcare, research, education, or medical communications, this congress can be a very strong source of qualified leads.
6) Estimated attendance / expected footfall
For a congress like this, the expected attendance is usually best understood as a blend of scientific delegates, speakers, exhibitors, sponsors, and clinical visitors. The true footfall can vary depending on the year, the venue, and the strength of the scientific program.
Estimated footfall: Several thousand attendees, typically including a strong international delegate mix.
What matters more than raw volume is attendee quality. This event tends to draw professionals with clear influence over:
- therapy adoption
- guideline alignment
- scientific advisory boards
- product launches
- research collaborations
- clinical purchasing and formulary decisions
In other words, the attendee count may be smaller than a mass-market expo, but the decision-maker density is often much higher.
7) Key focus areas & buyer engagement
EAS Congress 2026 is centered on the science and clinical management of atherosclerosis and related metabolic disease. That makes the buyer engagement especially valuable for companies that need access to specialists, evidence leaders, and treatment influencers.
Key focus areas:
- Atherosclerosis research
- Lipid metabolism and dyslipidemia
- Cardiovascular prevention
- Metabolic syndrome and cardiometabolic risk
- Familial hypercholesterolemia and inherited lipid disorders
- Clinical guidelines and treatment pathways
- Biomarkers, diagnostics, and risk stratification
- Novel therapies, biologics, and emerging treatment modalities
- Real-world evidence, outcomes research, and population health
- Academic research collaborations and translational science
Buyer engagement opportunities:
- Scientific sessions and abstract presentations
- Sponsored symposia
- Exhibition booth engagement
- One-to-one meetings with medical affairs and KOLs
- Product demonstrations for diagnostics and lab solutions
- Networking with hospital and university decision-makers
- Research partnerships and investigator outreach
The strongest engagement strategy is to position your offer around clinical relevance, scientific credibility, and specialist access. A generic attendee list pitch will underperform here; a disease-specific and role-specific buyer angle will perform much better.
8) Client-fit note: please share the client website before final buyer selection
To identify the best buyers for this event, I need to review your client’s website first. The right targets change significantly depending on what your client sells.
Examples:
- If your client sells pharma services, medical affairs support, or scientific communications, target medical affairs leaders, MSL heads, and clinical development teams.
- If your client sells diagnostic products or lab tools, target diagnostics marketing, lab managers, translational science teams, and research buyers.
- If your client sells healthcare software, data, or analytics, target real-world evidence teams, HEOR leaders, informatics heads, and clinical research operations.
- If your client sells training, consulting, or professional education, target academic faculty, society leaders, and specialist education decision-makers.
Once you share the client website, I can refine the buyer shortlist and make it much more precise based on product-market fit.
9) Industry suggestions based on the industry list
For this congress, the most appropriate industry filters from your list are:
- Pharmaceuticals
- Biotechnology
- Hospital & Health Care
- Medical Devices
- Research
- Higher Education
- Medical Practice
- Market Research
- Information Services
- Health, Wellness & Fitness
- Professional Training & Coaching
- Philanthropy
If you want to go even deeper, I would also recommend keyword filtering by disease area and function, such as:
- cardiology
- lipidology
- atherosclerosis
- cardiometabolic
- medical affairs
- clinical development
- outcomes research
- diagnostics
- biomarkers
- real-world evidence
Final recommendation
EAS Congress 2026 is a high-quality medical and scientific event for targeted attendee-list sales, especially if your client serves pharma, biotech, diagnostics, medical devices, research, or healthcare education. It is not a mass-market lead source, but it is a strong source of specialized, decision-influencing buyers.
Best buyer segments to collect:
- Medical affairs and MSL teams
- Clinical development and R&D leaders
- Diagnostics and lab technology buyers
- Hospital and academic medical center specialists
- HEOR, real-world evidence, and market access teams
- Scientific advisors, professors, and guideline experts
Quality rating for B2B attendee-list sales: 8.5/10
The event’s biggest strength is the concentration of specialist medical decision-makers. The main limitation is that it is niche and science-heavy, so list value depends heavily on matching the client’s offer to the right buyer group.
Next step: Please share your client website, and I will review it and tell you the best buyers to target from this event based on exact product fit.
Data sheet
| Event Name | 94th EAS Congress 2026 |
| Event Date | 24 May 2026 – 27 May 2026 |
| Event Status | Completed |
| Venue | Athens, Greece; exact venue name not publicly confirmed in the supplied brief. |
| City | Athens |
| State / Region | Attica |
| Country | Greece |
| Organizer | European Atherosclerosis Society (confirmed by society event branding; exact organizing entity name should be validated from the congress legal/registration page). |
| Official Event Website | eas-society.org |
| Event Type | Medical congress; cardiovascular research; lipidology; atherosclerosis; clinical science; biotech; pharmaceuticals; diagnostics; medical education |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Wellness, Health & Fitness |
| Audience Reach | Global scientific congress with strong European core attendance and international faculty, industry, and research participation. |
| Estimated Attendance / Expected Footfall | Likely several thousand delegates, based on the scale and standing of the annual EAS Congress. Attendance figure not publicly confirmed by the organizer in the reviewed brief. |
| Attendance Data Reliability | Estimated |
| Main Purpose of Event | To convene cardiology, lipidology, metabolism, vascular medicine, translational research, diagnostics, pharma, and biotech stakeholders for scientific exchange, clinical education, partnership building, therapeutic innovation, and commercial engagement in atherosclerosis and related cardiovascular disease management. |
The EAS Congress is the flagship annual scientific meeting associated with the European Atherosclerosis Society and is focused on atherosclerosis, dyslipidaemia, preventive cardiology, cardiovascular risk, genetics, biomarkers, therapeutics, and clinical translation. It attracts a specialized professional audience rather than broad consumer traffic, making it highly relevant for pharmaceutical, biotech, diagnostics, clinical research, and medical education stakeholders.
From a commercial and lead-generation perspective, the event matters because it gathers clinically influential physicians, academic researchers, hospital specialists, guideline contributors, industry medical affairs teams, R&D leaders, and relevant solution providers in one setting. It is particularly valuable for scientific networking, KOL engagement, partnership development, trial awareness, disease-area marketing, diagnostics positioning, and institutional outreach into cardiovascular and metabolic care ecosystems.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Cardiologists and preventive cardiology specialists | University hospitals, cardiovascular institutes, private hospitals, specialist clinics | Clinical influence, therapy adoption, prescribing input, guideline discussion | High relevance for pharma, diagnostics, education, clinical software, and research solutions |
| Lipidologists, endocrinologists, internists, and vascular medicine experts | Academic medical centers, metabolic clinics, hospital departments | Disease-area expertise, treatment pathway influence, biomarker and diagnostics adoption | High relevance for lipid-lowering therapeutics, lab platforms, patient management tools |
| Clinical researchers and principal investigators | Universities, research hospitals, translational science centers, clinical trial units | Research collaboration, trial participation, publication influence, evidence generation | Critical for CROs, biotech partnerships, assay providers, and scientific platforms |
| Hospital decision-makers and departmental leaders | Hospital networks, university medical centers, specialty institutes | Procurement influence, evaluation committees, budget input, service-line strategy | Important for diagnostics, lab equipment, clinical informatics, training, and service contracts |
| Pharmaceutical medical affairs and clinical development teams | Branded pharma, specialty pharma, cardiovascular and metabolic therapy companies | Scientific engagement, KOL mapping, clinical education, launch support, evidence strategy | High-value audience for congress services, data providers, education vendors, and partnerships |
| Biotech and translational medicine teams | Emerging biotech firms, genomic medicine companies, cardiovascular innovation ventures | Licensing, partnering, pipeline validation, investigator networking | Strong fit for partnering outreach, R&D collaboration, and trial ecosystem services |
| Diagnostics and laboratory technology buyers | Clinical labs, reference labs, hospital pathology and chemistry departments | Assay evaluation, platform comparison, biomarker implementation | Relevant for lipid testing, genetic diagnostics, biomarker analytics, and lab automation suppliers |
| Association leaders, guideline experts, and educators | Professional societies, medical education organizations, advocacy groups | Thought leadership, educational agenda shaping, endorsement influence | Useful for accredited education, awareness campaigns, and scientific communication vendors |
| Industry partnerships and market access teams | Pharma, biotech, diagnostics, market access consultancies | Strategic alliances, value dossier development, payer-facing evidence planning | Relevant for HEOR, evidence generation, medical communications, and partnership outreach |
| Scientific media and specialist publishers | Medical journals, healthcare media, scientific news platforms | Awareness amplification, publication support, visibility influence | Secondary value for PR, scientific launches, and educational dissemination |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Athens | Local physicians, university faculty, hospitals, labs, and medical organizations | Medium | Host-city uplift likely supports local hospital and academic participation. |
| Attica / Wider Greece | National cardiology, internal medicine, endocrinology, and academic networks | Medium | Greek clinical and research institutions likely represented due to location advantage. |
| Southern and Eastern Europe | Regional physicians, researchers, and industry teams from nearby EU and neighboring markets | High | Athens is accessible for cross-border European scientific travel. |
| Europe-wide | Core EAS community, universities, hospitals, pharma regional teams, diagnostic firms | Very High | Primary attendee base expected to be European given the society footprint and disease-area relevance. |
| North America | Selected academic faculty, biotech, global pharma, and collaborative research groups | Medium | Likely represented through faculty, sponsors, and multinational therapeutic developers. |
| Middle East and Asia-Pacific | Specialist clinicians, researchers, and global life-sciences companies | Low to Medium | International reach is likely, but organizer-reviewed public brief does not confirm country-by-country attendance. |
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The congress serves an international scientific and medical audience, with Europe as the strongest attendance base and additional participation expected from multinational pharma, global faculty, and international research institutions. |
| Secondary Reach Description | Pan-European core | The society identity and subject matter strongly position the event as one of the key European specialist meetings in atherosclerosis and lipid science. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Public current-year buyer organization list not publicly confirmed | Data availability note | The organizer brief reviewed does not publish a validated attendee directory. | eas-society.org | Congress Manager; Sponsorship Manager; Medical Affairs Director | Confirmed Organizer |
| University hospitals with lipid clinics and cardiovascular departments | Institutional buyer segment | High-probability attendee segment for clinical and scientific congress participation. | Not applicable | Professor of Cardiology; Department Head; Lab Director | Likely attendee profile |
| Academic medical centers in cardiology, endocrinology, and vascular medicine | Institutional buyer segment | Relevant for research collaboration, diagnostics evaluation, and education partnerships. | Not applicable | Clinical Research Director; PI; Head of Lipid Clinic | Likely attendee profile |
| Cardiovascular-focused pharmaceutical companies | Industry buyer / partner segment | Relevant for medical affairs, congress partnerships, KOL engagement, and therapy-area positioning. | Not applicable | Medical Affairs Director; Congress Lead; Brand Director | Likely attendee profile |
| Biotech companies developing lipid, metabolic, or cardiovascular assets | Industry buyer / partner segment | Highly relevant for licensing, investigator engagement, and scientific validation. | Not applicable | VP Clinical Development; Translational Medicine Lead; BD Director | Likely attendee profile |
| Diagnostics and biomarker testing companies | Commercial buyer / supplier segment | Direct fit for lipid analytics, genetic testing, and cardiovascular biomarker workflows. | Not applicable | Commercial Director; Product Manager; Market Development Lead | Likely attendee profile |
| Clinical laboratories and reference lab networks | Institutional buyer segment | Relevant for testing platforms, assay adoption, and data interpretation tools. | Not applicable | Lab Director; Pathology Director; Procurement Manager | Likely attendee profile |
| Contract research organizations supporting cardiovascular trials | Service buyer / partner segment | Important for trial execution, site recruitment, and scientific partnership discussions. | Not applicable | Therapeutic Area Lead; Site Network Director; Partnerships Director | Likely attendee profile |
| Professional societies and guideline bodies in cardiology and metabolism | Association buyer / partner segment | Relevant for scientific communication, educational partnerships, and expert network access. | Not applicable | Education Director; Society Executive; Scientific Affairs Lead | Likely attendee profile |
| Medical education and scientific communications agencies | Service buyer / partner segment | Relevant for satellite symposia, HCP engagement, content activation, and scientific dissemination. | Not applicable | Account Director; Scientific Director; Client Partnerships Lead | Likely attendee profile |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Professor of Cardiology / Preventive Cardiology Lead | Clinical / Academic | Director / Department Head | High scientific influence, therapy adoption, trial collaboration, and education value. |
| 2 | Head of Lipid Clinic / Lipidologist | Clinical | Manager / Director | Core disease-area decision-maker for lipid testing, patient pathways, and therapeutics. |
| 3 | Principal Investigator / Clinical Research Director | Research | Director / Senior | Key for clinical studies, translational partnerships, and scientific platform adoption. |
| 4 | Medical Affairs Director | Medical Affairs | Director / VP | Controls congress engagement, KOL strategy, education initiatives, and medical content. |
| 5 | Clinical Development Director | R&D / Clinical Development | Director / VP | Important for trial planning, site selection, and collaboration with research hospitals. |
| 6 | Market Access Director | Market Access | Director / Senior | Relevant for evidence messaging, value communication, and therapy commercialization. |
| 7 | Laboratory Director / Clinical Chemistry Lead | Laboratory / Diagnostics | Director | Key for assay evaluation, biomarker workflows, and diagnostics procurement input. |
| 8 | Hospital Procurement Manager | Procurement | Manager | Relevant for diagnostics platforms, lab consumables, education services, and medical technology purchases. |
| 9 | Business Development Director | Business Development / Partnerships | Director / VP | High relevance for licensing, collaboration, co-development, and scientific alliances. |
| 10 | Congress / Events Lead | Commercial / Medical Affairs / Events | Manager / Director | Directly controls sponsorship, exhibitor activations, satellite education, and delegate engagement programs. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Core audience includes hospitals, specialty clinics, and cardiovascular care systems. | Clinical adoption, procurement, service-line partnerships |
| 2 | Pharmaceuticals | Therapeutic innovation and medical affairs participation are central to the congress. | Medical affairs, brand strategy, KOL engagement |
| 3 | Biotechnology | Emerging cardiovascular and metabolic pipelines align strongly with the event. | Licensing, clinical collaboration, translational science |
| 4 | Medical Devices | Relevant where cardiovascular monitoring, intervention support, or diagnostics interfaces apply. | Specialist clinical outreach and hospital targeting |
| 5 | Research | The event has a strong translational and academic science component. | PI mapping, academic collaboration, site recruitment |
| 6 | Higher Education | University medical centers and academic departments are likely prominent. | Faculty engagement, research partnerships, education programs |
| 7 | Health, Wellness & Fitness | Preventive cardiology and patient lifestyle management create adjacent relevance. | Prevention tools, patient engagement, care optimization |
| 8 | Information Technology & Services | Relevant for clinical data tools, digital health, analytics, and education platforms. | Clinical informatics, digital engagement, analytics solutions |
| 9 | Computer Software | Useful where registries, imaging analytics, trial software, or HCP education tools are involved. | Software-led hospital and research sales |
| 10 | Events Services | Congress organizers, medical event vendors, and sponsorship service providers are relevant around the event ecosystem. | Exhibitor support, delegate engagement, event activation |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Likely several thousand | Estimated | Based on the congress scale, specialty standing, and annual international format | Attendance figure not publicly confirmed by the organizer. |
| Exhibitor count | Not publicly confirmed | Unconfirmed | Requires official exhibitor or sponsor directory review | Medical congress exhibitions are typically targeted and sponsor-led rather than broad trade floor volume. |
| Buyer count | Not publicly confirmed | Unconfirmed | No validated buyer registration breakdown published in the reviewed brief | Buyer mix is specialized and institutionally influenced rather than retail-style attendance. |
| Speaker count | Not publicly confirmed | Unconfirmed | Requires final scientific programme review | Expected to include substantial faculty due to multi-day scientific sessions. |
| Sponsor count | Not publicly confirmed | Unconfirmed | Requires official sponsor page review | Typically relevant for pharma, biotech, diagnostics, and medical education partners. |
| Historical attendance | Prior-year public figures not validated in this brief | Historical / prior-year evidence needed | Official prior congress reports and registration announcements | Should be checked before using for forecasting or sales claims. |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Atherosclerosis research | Access to latest evidence, mechanistic science, and trial updates | KOL engagement, research collaboration, abstract-led outreach | Research platforms, trial support, scientific services |
| Lipid management and dyslipidaemia | Therapy optimization, guideline interpretation, patient stratification | Medical affairs meetings, evidence education, product positioning | Pharma therapies, diagnostic assays, decision-support tools |
| Preventive cardiology | Risk prediction, early intervention, care pathway improvement | Population-health dialogue, clinic workflow solutions | Digital health, analytics, prevention programs |
| Diagnostics and biomarkers | Improved testing sensitivity, interpretation, and implementation | Lab director outreach, assay demonstrations, validation discussions | Biomarker panels, lab systems, genetic testing, software analytics |
| Clinical trials and translational medicine | Investigator networks, site recruitment, protocol collaboration | PI meetings, partnering sessions, R&D networking | CRO support, trial technology, biostatistics, patient recruitment solutions |
| Medical education | Accredited education, scientific updates, HCP learning engagement | Satellite symposia, faculty-led sessions, content partnerships | Education platforms, scientific communications, event support |
| Commercial partnerships | Licensing, co-development, strategic visibility, market access alignment | Executive meetings, alliance outreach, sponsor activations | Partnering services, BD intelligence, launch support |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | The audience is specialized and concentrated around high-value healthcare, research, and life-sciences decision ecosystems. |
| Decision-maker availability | High | Department heads, medical affairs leaders, investigators, and clinical specialists are likely present. |
| Data collection potential | Medium | High-value audience, but public attendee lists are often restricted in medical congress settings. |
| Apollo targeting potential | High | The buyer universe can be mapped effectively by therapy area, institution type, industry, and medical-affairs functions. |
| Geographic targeting potential | High | Pan-European targeting with selective global expansion is practical and relevant. |
| Best outreach approach | High-value scientific and solution-led outreach | Use evidence-based messaging, clinical relevance, research alignment, and institution-specific pain points rather than generic sales copy. |
| Overall lead quality | High | The event is strong for specialized B2B healthcare list building, KOL mapping, and institutional targeting, though list access may be less open than commercial expos. |
| Best use case | ABM, partnership outreach, medical affairs mapping, research collaborations | Most valuable for focused, high-consideration healthcare outreach rather than mass-volume prospecting. |
| Limitations / risks | Medium | Medical compliance, attendee privacy, and limited public attendee disclosure reduce certainty around named-participant list building. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Pharmaceuticals; Biotechnology; Medical Devices; Research; Higher Education; Information Technology & Services; Computer Software; Health, Wellness & Fitness | Captures the main clinical, scientific, and commercial audience groups. |
| Departments | Medical Affairs; Research; Clinical Development; Business Development; Procurement; Operations; Laboratory; Education; Marketing | Aligns with congress participation and downstream buying influence. |
| Seniority | Director; VP; Head; CXO; Partner; Owner; Manager; Senior | Targets both institutional decision-makers and specialist functional leaders. |
| Job titles | Medical Affairs Director; Clinical Development Director; Professor of Cardiology; Head of Lipid Clinic; Principal Investigator; Lab Director; Market Access Director; Business Development Director; Research Director; Hospital Procurement Manager | High-fit contacts most likely to engage around the congress themes. |
| Geography | Greece; United Kingdom; Germany; France; Italy; Spain; Netherlands; Switzerland; Belgium; Austria; Nordics; Ireland; selected North America accounts | Best for pan-European and multinational life-sciences prospecting. |
| Employee size | 51-200; 201-500; 501-1000; 1001-5000; 5001-10000; 10000+ | Covers scale-appropriate biotechs, diagnostics firms, hospitals, and multinational pharma. |
| Keywords | atherosclerosis; lipidology; dyslipidemia; cardiology; preventive cardiology; cardiovascular; metabolic disease; biomarkers; lipid clinic; FH; LDL; outcomes research | Improves disease-area precision beyond industry-only targeting. |
| Technologies, if relevant | Clinical trial systems; lab informatics; digital health; registry platforms; education platforms | Useful for software and services vendors selling into the congress audience. |
| Revenue range, if relevant | $10M+ for specialist biotechs and agencies; $100M+ for established diagnostics and pharma | Helps prioritize commercially mature organizations with congress budgets and partnership capacity. |
| Company type | Public companies; private companies; nonprofit organizations; educational institutions; hospital systems | Captures the mix of industry and institution-side attendees. |
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| European Atherosclerosis Society | Official organizer / society website | Organizer identity, congress positioning, therapeutic focus area, annual congress context | High |
| EAS Events / Congress Pages | Official event listing | Event existence, annual congress structure, event-level confirmation pathway | High |
| Supplied event brief from requester | User-provided event data | City, region, country, date range, event description, and indicative attendee profile | Medium |
| Official congress programme / sponsor / exhibitor / registration pages | Primary-source validation recommended | Would verify venue name, exhibitor count, sponsor count, faculty organizations, and any current-year participant evidence | High when available |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 94th EAS Congress 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.